NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled